Quanterix Posts $35M in Third-Quarter Revenue
QTRX sits 35% above its 52-week low of $2.15.
Summary
Quanterix reported third-quarter revenue of $35M and third-quarter net income of USD -21.591 Million. The company narrowed its 2026 revenue outlook to $142M–$146M, after having cut full-year 2026 revenue guidance by roughly 15% in August, when it also missed Q2 revenue expectations, pushed cash flow breakeven to 2027, and took a $26.9M goodwill impairment. With a small market cap, the stock is sensitive to any sign of stabilization in the core business. The October NMPA approval in China for the HD-X and SR-X instruments and four neurology assays with partner Innovita is a potential revenue contributor, but timing and ramp are not quantified.
At the time of this announcement, QTRX was trading at $2.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $136.9M. The 52-week trading range was $2.15 to $8.77. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.